Curis, Inc. (CRIS) Raised to “Hold” at ValuEngine
ValuEngine upgraded shares of Curis, Inc. (NASDAQ:CRIS) from a sell rating to a hold rating in a report released on Friday morning.
Other equities analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Curis from a hold rating to a sell rating in a research note on Wednesday, May 10th. Cowen and Company reiterated a buy rating on shares of Curis in a research note on Friday, May 5th. Finally, BidaskClub lowered shares of Curis from a hold rating to a sell rating in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Curis presently has a consensus rating of Hold and an average target price of $5.88.
Shares of Curis (NASDAQ:CRIS) traded up 2.45% on Friday, hitting $2.09. 807,696 shares of the stock were exchanged. The company’s 50 day moving average is $1.84 and its 200-day moving average is $2.16. The stock’s market cap is $300.71 million. Curis has a 52-week low of $1.47 and a 52-week high of $3.72.
Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The company had revenue of $2.10 million during the quarter, compared to analysts’ expectations of $2.08 million. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.09) earnings per share. Analysts predict that Curis will post ($0.40) EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Curis by 6.7% during the first quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock worth $13,421,000 after acquiring an additional 304,268 shares during the last quarter. Prudential Financial Inc. purchased a new position in shares of Curis during the first quarter worth approximately $105,000. Perceptive Advisors LLC purchased a new position in shares of Curis during the first quarter worth approximately $1,390,000. American International Group Inc. grew its position in shares of Curis by 7.1% during the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after acquiring an additional 4,560 shares during the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in shares of Curis during the first quarter worth approximately $408,000. Institutional investors and hedge funds own 50.94% of the company’s stock.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.